Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
- To investigate the safety of letrozole monotherapy at a dose 1.0 mg/day or fadrozole
monotherapy at a dose 2.0mg in Japanese postmenopausal patients with advanced breast cancer
which participated in double blind study.